Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of flexible
dosages of paliperidone ER as compared with placebo in patients with schizophrenia who are 65
years of age or older. The primary objective of the open-label extension is the long-term
assessment of safety and tolerability of paliperidone ER in patients diagnosed with
schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.